On October 6-7, 2016, a meeting of representatives of national trial groups was held at Scandic Stortoget Hotel in Malmö. CEEGOG was represented by its chairman Prof. David Cibula and the administrative manager Mrs. Ivana Nohová.
The Engot Admin meeting was focused on ENGOT documentation, risk based monitoring and budgeting a trial, monitoring network, on EU regulation and the GCP amendment.
The ENGOT Administrative meeting was followed by the ENGOT assembly meeting. The main topic involved trial activities and the status of collaboration. Group participation in ENGOT studies was also evaluated. Prof. David Cibula delivered a presentation on the ABRAX proposal of CEEGOG. It was decided that this could be an ENGOT tial. All groups showed interest in ABRAX. Other topics for discussion were as follows: privileged partnership application of EVA group (Brazil), new PGOG application, update of publication rules and reports from the ESGO council and working groups.
More information may be provided by the CEEGOG office on request.
The Gynaecological Cancer Academy (GCA), which is run by ENGOT, sets itself the goal of nurturing and developing the next generation of leaders in gynaecological oncology in order to ensure continuity and the transfer of knowledge and experience among members of the clinical trial community.
The 8th GCA workshop took place in Baveno on September 30, 2016. CEEGOG was represented by two physicians, namely Dr. Jaroslav Klát (University Hospital in Ostrava) and Dr. Roman Kocián (General University Hospital in Prague).
The main topic of the workshop was Non-ovarian cancer. The most important presentations of the training module are webcasted and available on ESGO eAcademy.
We would like to inform you that our Association has endorsed the CEEGOG membership application of the Maribor center. We are pleased that CEEGOG has been expanding and currently includes centers from 4 countries - the Czech Republic, Slovakia, Poland and newly Slovenia.
It is our great pleasure to let you know that the protocol for the SENTIX trial (SENTinel lymph node in cervIX cancer) has been finished and the trial is now ready for new centers to join it and for new patients to be enrolled in.
SENTIX is a prospective observational international multicenter trial on sentinel lymph node biopsy in patients with early stage of cervical cancer. Our target is to enroll 300 patients and this could be achieved until the end of 2017.The trial chair is David Cibula, and the main investigator is Roman Kocian (General University Hospital in Prague, CZ).
Since the SENTIX is the original CEEGOG trial it is our hope that the majority of CEEGOG centers will participate in it.
We are looking forward to our prospective mutual cooperation. For futher information or if you have any queries, please do not hesitate to contact the CEEGOG office.
We would like to update you on the change of the CEEGOG residence. The proposal for the new place of residence was approved by all participants at the CEEGOG meeting in April 2016. Starting April 20, 2016, the Association resides in the city of Prague.
The GCA targets translational research, Phase 1/Phase 2 trials and Ph1 drugs development involving researchers and specialist in Ph1-2 clinical studies.
The 7th GCA workshop took place in Copenhagen on May 13 – 14, 2016. CEEGOG was represented by three physicians, Jaroslav Klát (University Hospital in Ostrava), Michal Zikán (General University Hospital in Prague) and Roman Kocián (General University Hospital in Prague).
During this creative meeting, which was supervised by Prof. Ignace Vergote (Chair) and Antonio Casado (Co-Chair) national network representatives presented phase 1, 2 trial proposals. Prof. Cristiana Sessa delivered a key note lecture focused on how Phase 1/2 should be carried on and how Phase 1 trials are being managed in Bellinzona Oncology Institute in Southern Switzerland. Dr. Mirza Mansoor (Dep. of Oncology, Copenhagen University Hospital) introduced a Ph 2 randomized Umbrella Trial in Recurrent Ovarian Cancer combining PD-L1 antagonist Durvalumab with an agent targeting immunosuppression in the tumor bed (AZD 5069, AZD 9150) as a complementary antitumor strategy. Later, individual proposals were discussed and remarked. The high importance of the annual meeting with ENGOT support was emphasised and it was agreed to continue discussion via a teleconference in June 2016.
Should you need futher information, you are welcome to contact the CEEGOG office.
We are very pleased to announce that the trial on the role of HE4 in the follow-up of advanced ovarian, Fallopian tube and primary peritoneal cancer has been opened for the enrollment. Since the calculated size of the group is relatively small (150), we are conviced the enrollment will be complete within a relatively short time. We consider this trial to be a great opportunity for CEEGOG and some other centers.
The Principal investigators are Jiri Presl (UH Pilsen, CZ) and Vit Weinberger (UH Brno, CZ).
We are looking forward to cooperating with you and we really appreciate your support for this trial. For more information, please do not hesitate to contact CEEGOG office.
We would like to invite CEEGOG members and colleagues to the annual joint CEEGOG meeting, which is going to be held at the Diplomat Hotel Prague in Prague on Wednesday afternoon (17:00 pm – 22:00 pm) on 20th April 2016, one day before the IVW (www.ivw-prague.cz).
On 4th March, representatives of national trial groups had an appointment at the Sheraton Airport Hotel in Frankfurt. CEEGOG was represented by its chairman Prof. David Cibula and administrative manager Ivana Nohová. In addition to ongoing and new clinical trials, the Report from the ESGO council, the European Ovarian Cancer Consensus meeting (ESMO/ESGO) and New strategic goals, were discussed.
The ENGOT administrative meeting was held the day before. The main topics were as follows: Risk based monitoring, Trial budgeting and the ENGOT monitoring network.
If you would like more information, please contact the CEEGOG admin office.
On 23rd October, a meeting of representatives of national trial groups was held at Acropolis Congress Center. CEEGOG was represented by its vice-chairman prof. Miloš Mlynček and administrative manager Taťána Růžičková. Ongoing clinical trials were discussed, as well as non trial activities . In addition to clinical trials, the main topics were : ENGOT elections 2016-2020, the Report from the ESGO council, the European Ovarian Cancer Consensus meeting(ESMO/ESGO/ESTRO/and ENGOT strategic goals. For more information, please contact the CEEGOG admin office.
The 19th Biannual Meeting of the European Society of Gynecological Oncology (ESGO 2015) was held from24th to 27th October. For the first time, an Awareness Run, to raise awareness of early detection of cervical cancer and HPV vaccination programs, was organized by the ESGO at this year's congress in Nice. The run activity's goal was to encourage a healthy life style, which directly affects gynecological cancer incidents. Over 250 delegates registered for the 5 km race. One of CEEGOG members, associate professor Jiří Sláma, finished the race in second place. Congratulations.
We would like to welcome a new member of our collaborative group – Department of Gynecological Oncology, Holycross Cancer Center, Kielce, Poland – represented by Marcin Misiek MD and Kamil Zalewski MD.
Page 5 of 6